Cargando…
Janus Kinase Signaling: Oncogenic Criminal of Lymphoid Cancers
SIMPLE SUMMARY: Janus kinases (JAKs) are transmembrane receptors that pass signals from extracellular ligands to downstream. Increasing evidence has suggested that JAK family aberrations promote lymphoid cancer pathogenesis and progression through mediating gene expression via the JAK/STAT pathway o...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8533975/ https://www.ncbi.nlm.nih.gov/pubmed/34680295 http://dx.doi.org/10.3390/cancers13205147 |
_version_ | 1784587443446480896 |
---|---|
author | Li, Boheng Wan, Qin Li, Zhubo Chng, Wee-Joo |
author_facet | Li, Boheng Wan, Qin Li, Zhubo Chng, Wee-Joo |
author_sort | Li, Boheng |
collection | PubMed |
description | SIMPLE SUMMARY: Janus kinases (JAKs) are transmembrane receptors that pass signals from extracellular ligands to downstream. Increasing evidence has suggested that JAK family aberrations promote lymphoid cancer pathogenesis and progression through mediating gene expression via the JAK/STAT pathway or noncanonical JAK signaling. We are here to review how canonical JAK/STAT and noncanonical JAK signalings are represented and deregulated in lymphoid malignancies and how to target JAK for therapeutic purposes. ABSTRACT: The Janus kinase (JAK) family are known to respond to extracellular cytokine stimuli and to phosphorylate and activate signal transducers and activators of transcription (STAT), thereby modulating gene expression profiles. Recent studies have highlighted JAK abnormality in inducing over-activation of the JAK/STAT pathway, and that the cytoplasmic JAK tyrosine kinases may also have a nuclear role. A couple of anti-JAK therapeutics have been developed, which effectively harness lymphoid cancer cells. Here we discuss mutations and fusions leading to JAK deregulations, how upstream nodes drive JAK expression, how classical JAK/STAT pathways are represented in lymphoid malignancies and the noncanonical and nuclear role of JAKs. We also summarize JAK inhibition therapeutics applied alone or synergized with other drugs in treating lymphoid malignancies. |
format | Online Article Text |
id | pubmed-8533975 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-85339752021-10-23 Janus Kinase Signaling: Oncogenic Criminal of Lymphoid Cancers Li, Boheng Wan, Qin Li, Zhubo Chng, Wee-Joo Cancers (Basel) Review SIMPLE SUMMARY: Janus kinases (JAKs) are transmembrane receptors that pass signals from extracellular ligands to downstream. Increasing evidence has suggested that JAK family aberrations promote lymphoid cancer pathogenesis and progression through mediating gene expression via the JAK/STAT pathway or noncanonical JAK signaling. We are here to review how canonical JAK/STAT and noncanonical JAK signalings are represented and deregulated in lymphoid malignancies and how to target JAK for therapeutic purposes. ABSTRACT: The Janus kinase (JAK) family are known to respond to extracellular cytokine stimuli and to phosphorylate and activate signal transducers and activators of transcription (STAT), thereby modulating gene expression profiles. Recent studies have highlighted JAK abnormality in inducing over-activation of the JAK/STAT pathway, and that the cytoplasmic JAK tyrosine kinases may also have a nuclear role. A couple of anti-JAK therapeutics have been developed, which effectively harness lymphoid cancer cells. Here we discuss mutations and fusions leading to JAK deregulations, how upstream nodes drive JAK expression, how classical JAK/STAT pathways are represented in lymphoid malignancies and the noncanonical and nuclear role of JAKs. We also summarize JAK inhibition therapeutics applied alone or synergized with other drugs in treating lymphoid malignancies. MDPI 2021-10-14 /pmc/articles/PMC8533975/ /pubmed/34680295 http://dx.doi.org/10.3390/cancers13205147 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Li, Boheng Wan, Qin Li, Zhubo Chng, Wee-Joo Janus Kinase Signaling: Oncogenic Criminal of Lymphoid Cancers |
title | Janus Kinase Signaling: Oncogenic Criminal of Lymphoid Cancers |
title_full | Janus Kinase Signaling: Oncogenic Criminal of Lymphoid Cancers |
title_fullStr | Janus Kinase Signaling: Oncogenic Criminal of Lymphoid Cancers |
title_full_unstemmed | Janus Kinase Signaling: Oncogenic Criminal of Lymphoid Cancers |
title_short | Janus Kinase Signaling: Oncogenic Criminal of Lymphoid Cancers |
title_sort | janus kinase signaling: oncogenic criminal of lymphoid cancers |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8533975/ https://www.ncbi.nlm.nih.gov/pubmed/34680295 http://dx.doi.org/10.3390/cancers13205147 |
work_keys_str_mv | AT liboheng januskinasesignalingoncogeniccriminaloflymphoidcancers AT wanqin januskinasesignalingoncogeniccriminaloflymphoidcancers AT lizhubo januskinasesignalingoncogeniccriminaloflymphoidcancers AT chngweejoo januskinasesignalingoncogeniccriminaloflymphoidcancers |